Syn­er­gy out­lines up­beat PhI­II da­ta; Blue­bird and Blue­print rais­ing $375M

Syn­er­gy Phar­ma­ceu­ti­cals $SGYP is fol­low­ing up on the late-stage suc­cess of its lead drug ple­ca­natide for chron­ic id­io­path­ic con­sti­pa­tion with a new batch of up­beat Phase III da­ta cen­tered on ir­ri­ta­ble bow­el syn­drome with con­sti­pa­tion. The study was con­duct­ed among 1,135 pa­tients and the biotech says it will now fol­low up with a new ap­pli­ca­tion in Q1 2017. Syn­er­gy is al­ready look­ing at a PDU­FA date of Jan­u­ary 29 for its first in­di­ca­tion. The com­pa­ny’s shares spiked 6% on the news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER